Results 11 to 20 of about 993 (163)

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Journal of Fungi (Basel, Switzerland)
The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin.
Simin Yang, Huiping Lin, Feifei Wan
exaly   +4 more sources

Intravitreal rezafungin and anidulafungin in a rabbit model of Aspergillus fumigatus endophthalmitis [PDF]

Scientific Reports
Rezafungin (RZF) and anidulafungin (AFG) are echinocandins with potential for treating Aspergillus fumigatus endophthalmitis. We evaluated their antifungal and anti-inflammatory effects in vitro and in a rabbit endophthalmitis model.
Yue Zhang, Yanjie Zhou, Yi Tang, Hong Wu
doaj   +3 more sources

A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin [PDF]

IDCases
Antifungal resistance in Candida glabrata can develop to different classes of drugs, including the azoles and echinocandins. This organism is known to cause infective endocarditis with a particular predilection for prosthetic valves.
Divya Chandramohan, Samantha Aguilar, Gerard Gawrys, Nathan P. Wiederhold, Kristi Traugott, Thomas F. Patterson   +5 more
doaj   +4 more sources

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials. [PDF]

Mycoses
ABSTRACT Background The efficacy and safety of rezafungin in invasive candidiasis (IC) and candidaemia was demonstrated in the Phase 2 STRIVE and Phase 3 ReSTORE trials, and an additional cohort of patients in ReSTORE from China (ReSTORE China). Objectives This post hoc analysis is the first time that combined data from all double‐blind, randomised ...
Soriano A, Thompson GR, Cornely OA, Bassetti M, Kullberg BJ, Honoré PM, Dupont H, Vazquez JA, Huang H, Zhang Y, Dickerson S, Cox L, Pappas PG.   +12 more
europepmc   +3 more sources

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models

Journal of Fungi, 2021
Rezafungin is a novel echinocandin in Phase 3 development for prevention of invasive fungal disease caused by Candida spp., Aspergillus spp. and Pneumocystis jirovecii in blood and marrow transplantation patients.
Melanie T. Cushion, Alan Ashbaugh
doaj   +2 more sources

Activity of rezafungin against Candida auris [PDF]

Journal of Antimicrobial Chemotherapy
Abstract The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality.
Jalāl A Aram, Jeffrey Locke, Voon Ong
exaly   +4 more sources

Rezafungin in fluconazole-resistant and refractory candidiasis: the first Brazilian experience. [PDF]

Rev Inst Med Trop Sao Paulo
ABSTRACT Invasive candidiasis is associated with high morbidity and mortality, and the rising of antifungal resistance underscores the need for new therapies. Rezafungin, a second-generation echinocandin, enables once-weekly dosing, achieves high plasma concentrations, and shows potent in vitro activity.
Kruschewsky WLL, Nakagawa JAS, Siqueira LPM, Taborda M, de Oliveira VF, Abdala E, Magri ASGK, Magri MMC.   +7 more
europepmc   +6 more sources

Efficacy of rezafungin in a case of Candida spondylodiskitis [PDF]

Journal of Bone and Joint Infection
Rezafungin, which only requires weekly administration, is a potential candidate for difficult-to-treat infections that require long-term antimicrobial treatment, such as bone and joint infections.
M. Lahouati, M. Lahouati, C. Tinévez, C. Tinévez, F. Gabriel, F. Xuereb, F. Xuereb, M. Lefranc, F.-A. Dauchy, F.-A. Dauchy   +9 more
doaj   +5 more sources

EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Rezafungin is a new long-acting echinocandin currently in phase 3 development. Epidemiological cutoff values are necessary for breakpoint setting but have not been established due to unexplained interlaboratory MIC variations observed in a prior multicenter study.
Maiken Cavling Arendrup, Karin Meinike Jørgensen, Rasmus Krøger Hare, Manuel Cuenca-Estrella, Oscar Zaragoza   +4 more
openaire   +4 more sources

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis [PDF]

Infection and Drug Resistance
Anna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj   +2 more sources